Most lab robots are expensive, inflexible, and live in a corner. Automata’s bet is that they should be modular, programmable, and central to the workflow. The London-based company has raised $152 million over eight rounds to prove it, with its latest $45 million Series C in January 2026 led by Dimension [Tracxn][Parsers VC, Jan 2026]. The money is buying space on the bench at The Francis Crick Institute and inside AstraZeneca’s labs, where its LINQ platform orchestrates everything from sample prep to imaging [TechCrunch, Oct 2023].
The Integrated Platform Wedge
Lab automation is not a new problem. Giants like Hamilton and Beckman Coulter have sold high-throughput systems for decades. Automata’s wedge is integration. Instead of a bespoke, single-purpose robot, it sells a hardware and software stack designed to be the central nervous system for a lab’s existing instruments. Its Eva robot arm is one component; the LINQ platform is the core, allowing teams to design, run, and manage multi-step, cross-functional processes from a single application [SelectScience].
The Capital Stack and Strategic Backers
Investor conviction has been steady, and the roster is telling. The $40 million round in October 2023 was led by Dimension, with participation from Octopus Ventures, Hummingbird, and A.P. Moller Holding [TechCrunch, Oct 2023]. The January 2026 $45 million Series C added Danaher Ventures, the corporate venture arm of the life sciences tools conglomerate, alongside Tru Arrow Partners and Entrepreneurs First [Parsers VC, Jan 2026].
| Metric | Value |
|---|---|
| 2022 Series B | 50 M USD |
| 2023 Series C | 40 M USD |
| 2026 Series C | 45 M USD |
Traction in Regulated Environments
Customer names validate the platform pitch. Automata lists NHS Trusts, including The Royal Marsden NHS Foundation Trust, academic powerhouses like The Francis Crick Institute, and pharma leaders AstraZeneca and bit.bio [Silicon Canals][Automata]. Its partnership with Molecular Devices integrates imaging and detection systems to create AI-ready, automated research workflows [Molecular Devices].
Where the Wheels Could Come Off
The bet is large and the capital burn is real. Automata operates in a capital-intensive hardware-plus-software category, competing with well-funded specialists and entrenched incumbents.
- Capital intensity. Building, deploying, and supporting physical robots in regulated environments is expensive.
- Competitive landscape. Opentrons targets the low-cost, high-volume academic and biotech segment. Hamilton and Beckman own the high-end, mission-critical liquid handling market.
- Operational rigor. Public records note layoffs and restructuring [LeadIQ]. Co-founder Suryansh Chandra resigned as a director in December 2021 [GOV.UK].
The Next Twelve Months
For CEO Mostafa ElSayed, the next phase is about scaling the installed base and proving the unit economics. The fresh $45 million provides runway to expand in Europe and the United States. Watch for two things: more announced enterprise deployments with global pharma names, and deeper product integrations with instruments from partners like Molecular Devices.